Beigene Ltd., of Waltham, Mass., reported dosing the first patient in a phase I trial of BGB-3111, a Bruton's tyrosine kinase inhibitor, in combination with BGB-A317, a PD-1 antibody, for the treatment of various B-cell malignancies. The study is designed to assess the safety, tolerability, pharmacokinetics and antitumor activities of that combination in patients with B-cell lymphoid malignancies. BGB-3111 will be dosed orally and BGB-A317 will be administered intravenously every three weeks. It is anticipated that about 25 patients will be enrolled into the study.